We have located links that may give you full text access.
CLINICAL TRIAL
JOURNAL ARTICLE
Percutaneous absorption and pharmacokinetics of eflornithine HCl 13.9% cream in women with unwanted facial hair.
Journal of Clinical Pharmacology 2001 September
This article reports the results of an open-label, multiple-dose study to determine percutaneous absorption and pharmacokinetics of eflornithine following topical treatment with eflornithine HCl 13.9% cream (Vaniqa). Ten women with excessive facial hair were treated with two 0.5 g single doses of [14C]-labeled eflornithine HCl 13.9% (w/w) cream (periods A and C) separated by twice-daily application of 0.5 g unlabeled eflornithine HCl 13.9% cream for 7 days (period B). Analysis of radioactivity excreted in urine and feces indicated that percutaneous absorption was minimal. Comparison with urinary excretion of eflornithine in period A suggested that most of absorbed eflornithine was excreted in urine without being metabolized. Radioactivity was not detectable in blood or plasma, but eflornithine concentrations were measurable, with peak concentrations of 4.96 ng/ml in period A and 10.44 ng/ml in period C. Eflornithine was eliminated from plasma with a mean terminal half-life of 11 hours (first application) and 8 hours (final application). Trough plasma concentrations reached steady state (4.61-5.50 ng/ml) after 4 days of twice-daily topical treatment, and multiple dosing had no apparent effect on disposition kinetics. The low degree of percutaneous absorption and low systemic exposure to eflornithine offer a favorable clinical safety profile of eflornithine HCl 13.9% cream.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app